Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for JANX

Stock NameJanux Therapeutics Inc
TickerJANX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS47103J1051

Show aggregate JANX holdings

News associated with JANX

Stifel Nicolaus Reiterates Buy Rating for Janux Therapeutics (NASDAQ:JANX)
Stifel Nicolaus restated their buy rating on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research report report published on Wednesday, Marketbeat Ratings reports. Stifel Nicolaus currently has a $45.00 price target on the stock. Other research analysts have also recently issued research reports about the company. Piper Sandler assumed coverage on Janux […] - 2025-09-11 04:40:25
The Math Shows SCHA Can Go To $31
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 09:07:38
Y Intercept Hong Kong Ltd Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
Y Intercept Hong Kong Ltd acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 17,833 shares of the company’s stock, valued at approximately $481,000. Other hedge funds and other institutional […] - 2025-07-28 06:14:50
Janux Therapeutics (NASDAQ:JANX) Research Coverage Started at Raymond James Financial
Raymond James Financial started coverage on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a report released on Friday, MarketBeat.com reports. The brokerage issued an outperform rating and a $65.00 price target on the stock. Janux Therapeutics Price Performance Janux Therapeutics stock opened at $25.15 on Friday. The firm has a market capitalization of […] - 2025-07-14 03:46:45
KBC Group NV Makes New $66,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)
KBC Group NV acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,461 shares of the company’s stock, valued at approximately $66,000. Other hedge funds and […] - 2025-07-09 04:33:52
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have been assigned an average rating of “Buy” from the eleven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to […] - 2025-06-26 04:34:55
Exchange Traded Concepts LLC Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
Exchange Traded Concepts LLC increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 20.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,043 shares of the company’s stock after buying an additional 686 shares during the period. Exchange Traded […] - 2025-06-25 04:56:58
SG Americas Securities LLC Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
SG Americas Securities LLC purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the first quarter, Holdings Channel reports. The fund purchased 28,631 shares of the company’s stock, valued at approximately $773,000. Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group […] - 2025-06-20 05:12:52
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 532.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,737 shares of the company’s […] - 2025-06-01 05:33:05
Two Sigma Investments LP Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
Two Sigma Investments LP lessened its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 22.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,974 shares of the company’s stock after selling 17,218 shares during the […] - 2025-05-30 04:50:55
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Squarepoint Ops LLC
Squarepoint Ops LLC grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 155.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,176 shares of the company’s stock after purchasing an additional 25,034 shares during the period. […] - 2025-05-29 05:18:55
ProShare Advisors LLC Purchases 2,003 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
ProShare Advisors LLC increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 23.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,384 shares of the company’s stock after acquiring an additional 2,003 shares during the quarter. ProShare […] - 2025-05-26 05:19:11
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has earned an average recommendation of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the […] - 2025-05-20 02:39:02
Deutsche Bank AG Has $4.98 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
Deutsche Bank AG raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 386.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,029 shares of the company’s stock after acquiring an additional 73,912 shares during the quarter. Deutsche Bank AG’s […] - 2025-05-19 04:55:22
Northern Trust Corp Purchases 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
Northern Trust Corp boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 15.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 308,800 shares of the company’s stock after acquiring an additional 42,302 shares during the quarter. Northern Trust Corp’s holdings in Janux Therapeutics were worth $16,533,000 as of its most […] - 2025-05-15 04:54:52
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider Selling
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) shares gapped down prior to trading on Monday after an insider sold shares in the company. The stock had previously closed at $32.88, but opened at $30.00. Janux Therapeutics shares last traded at $30.73, with a volume of 453,943 shares changing hands. Specifically, insider Andrew Hollman Meyer […] - 2025-05-07 02:20:58
Tower Research Capital LLC TRC Purchases 3,436 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
Tower Research Capital LLC TRC boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 878.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,827 shares of the company’s stock after purchasing an additional 3,436 shares during the period. Tower Research Capital LLC TRC’s […] - 2025-05-06 05:08:51
128,062 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by First Trust Advisors LP
First Trust Advisors LP purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 128,062 shares of the company’s stock, valued at approximately $6,856,000. Several other hedge funds have also made changes to their positions in JANX. […] - 2025-04-30 05:52:59
Marshall Wace LLP Sells 25,703 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
Marshall Wace LLP trimmed its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 53.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,348 shares of the company’s stock after selling 25,703 shares during the quarter. Marshall Wace LLP’s holdings […] - 2025-04-30 05:04:57
Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $95.25
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has been given an average recommendation of “Buy” by the eleven analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the […] - 2025-04-28 02:39:12
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Barclays PLC
Barclays PLC boosted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 51.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 263,970 shares of the company’s stock after purchasing an additional 89,909 shares during the period. […] - 2025-04-21 05:38:44
Orion Portfolio Solutions LLC Has $263,000 Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)
Orion Portfolio Solutions LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 25.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,913 shares of the company’s stock after selling 1,692 shares during the quarter. Orion Portfolio Solutions LLC’s […] - 2025-04-10 05:45:05
9,378 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Purchased by Sei Investments Co.
Sei Investments Co. acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,378 shares of the company’s stock, valued at approximately $502,000. Several other large investors also recently added to or […] - 2025-04-10 04:18:49
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Franklin Resources Inc.
Franklin Resources Inc. grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 2,519.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 497,287 shares of the company’s stock after purchasing an additional 478,304 shares during the quarter. Franklin Resources Inc. […] - 2025-04-07 06:11:08
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Corebridge Financial Inc.
Corebridge Financial Inc. trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 7.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,940 shares of the company’s stock after selling 1,053 shares during the period. Corebridge […] - 2025-04-07 04:32:49
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $92.44 Consensus Target Price from Analysts
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have been given a consensus rating of “Buy” by the twelve analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on […] - 2025-04-03 02:36:47
Bank of New York Mellon Corp Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
Bank of New York Mellon Corp trimmed its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 9.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 78,859 shares of the company’s stock after selling 7,976 shares during the quarter. Bank of New York Mellon Corp’s holdings in Janux Therapeutics were worth […] - 2025-03-19 05:08:43
Victory Capital Management Inc. Boosts Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)
Victory Capital Management Inc. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 715.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 242,409 shares of the company’s stock after buying an additional 212,664 shares during the quarter. Victory Capital Management […] - 2025-03-13 06:32:52
Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month Low After Analyst Downgrade
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report)’s stock price reached a new 52-week low during trading on Monday after Scotiabank lowered their price target on the stock from $62.00 to $41.00. Scotiabank currently has a sector perform rating on the stock. Janux Therapeutics traded as low as $31.67 and last traded at $31.68, with […] - 2025-03-05 04:54:56
New York State Common Retirement Fund Has $855,000 Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
New York State Common Retirement Fund increased its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 84.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 15,964 shares of the company’s stock after buying an additional 7,318 shares during the period. New York State Common Retirement Fund’s holdings in Janux Therapeutics […] - 2025-03-04 06:34:50

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc JANX holdings

DateNumber of JANX Shares HeldBase Market Value of JANX SharesLocal Market Value of JANX SharesChange in JANX Shares HeldChange in JANX Base ValueCurrent Price per JANX Share HeldPrevious Price per JANX Share Held
2025-09-26 (Friday)15,139USD 351,679USD 351,679
2025-09-25 (Thursday)15,139USD 329,576JANX holding decreased by -16199USD 329,5760USD -16,199 USD 21.77 USD 22.84
2025-09-24 (Wednesday)15,139USD 345,775USD 345,775
2025-09-17 (Wednesday)15,041USD 352,862JANX holding increased by 752USD 352,8620USD 752 USD 23.46 USD 23.41
2025-09-16 (Tuesday)15,041USD 352,110USD 352,110
2025-09-12 (Friday)14,943USD 359,379USD 359,379
2025-09-11 (Thursday)14,943JANX holding increased by 196USD 375,368JANX holding increased by 9495USD 375,368196USD 9,495 USD 25.12 USD 24.81
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of JANX by Blackrock for IE00B3VWM098

Show aggregate share trades of JANX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-11BUY196 25.120* 34.32
2025-08-21SELL-74 24.000* 34.38 Profit of 2,544 on sale
2025-07-31BUY222 24.015* 34.50
2025-06-30SELL-148 23.100* 35.71 Profit of 5,285 on sale
2025-06-25SELL-74 23.240* 35.97 Profit of 2,662 on sale
2025-06-20SELL-148 23.600* 36.24 Profit of 5,364 on sale
2025-05-23BUY74 25.220* 38.18
2025-05-19SELL-74 24.170* 38.63 Profit of 2,859 on sale
2025-05-15SELL-222 23.270* 38.90 Profit of 8,635 on sale
2025-05-12SELL-74 26.060* 39.28 Profit of 2,907 on sale
2025-05-09SELL-74 25.560* 39.40 Profit of 2,916 on sale
2025-04-30SELL-74 33.200* 40.09 Profit of 2,966 on sale
2025-04-24SELL-148 32.070* 40.41 Profit of 5,981 on sale
2025-04-17SELL-74 29.690* 40.97 Profit of 3,031 on sale
2025-04-15SELL-222 29.060* 41.23 Profit of 9,153 on sale
2025-04-14SELL-222 28.950* 41.36 Profit of 9,183 on sale
2025-04-09SELL-296 26.830* 41.84 Profit of 12,383 on sale
2025-04-07SELL-518 24.380* 42.25 Profit of 21,885 on sale
2025-04-04SELL-750 25.770* 42.44 Profit of 31,832 on sale
2025-03-31BUY75 27.000* 42.99
2025-03-19SELL-150 30.910* 44.36 Profit of 6,654 on sale
2025-03-14SELL-450 30.680* 44.92 Profit of 20,216 on sale
2025-03-13SELL-150 31.350* 45.12 Profit of 6,768 on sale
2025-03-12SELL-2,550 31.810* 45.31 Profit of 115,542 on sale
2025-03-07SELL-150 30.640* 46.00 Profit of 6,901 on sale
2025-03-06SELL-225 30.750* 46.24 Profit of 10,404 on sale
2025-03-03SELL-75 31.830* 46.97 Profit of 3,523 on sale
2025-02-28BUY10,306 32.890* 47.20
2025-02-26SELL-46 32.600* 47.71 Profit of 2,195 on sale
2025-02-25SELL-138 32.690* 47.97 Profit of 6,619 on sale
2025-02-18BUY230 37.090* 49.07
2025-02-13BUY46 37.170* 49.82
2025-02-12BUY46 36.780* 50.09
2025-02-11BUY138 36.110* 50.38
2025-02-06BUY414 40.680* 51.12
2025-01-27BUY46 43.540* 52.86
2024-12-30BUY230 52.500* 53.38
2024-12-06BUY184 64.990* 52.42
2024-12-05BUY46 66.300* 51.94
2024-12-04BUY230 66.835* 51.41
2024-11-29BUY230 45.210* 51.77
2024-11-27BUY184 46.390* 52.23
2024-11-26BUY46 48.000* 52.43
2024-11-21BUY230 46.500* 53.04
2024-11-20BUY138 48.960* 53.27
2024-11-18BUY552 48.120* 53.85
2024-11-12BUY368 52.840* 53.92
2024-11-08BUY230 53.920* 53.92
2024-11-07BUY690 54.210* 53.90
2024-11-06BUY92 54.890* 53.82
2024-10-31BUY46 53.990* 53.29
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of JANX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19172,634103260,40266.3%
2025-09-18176,5350269,33765.5%
2025-09-17128,85960187,77068.6%
2025-09-16100,2950143,49169.9%
2025-09-15108,2158167,20964.7%
2025-09-12150,5880185,35281.2%
2025-09-11108,5000160,95467.4%
2025-09-10201,7484256,59178.6%
2025-09-09113,1303,850173,14165.3%
2025-09-08300,5680543,09655.3%
2025-09-0562,6270127,57549.1%
2025-09-0472,7740124,26058.6%
2025-09-03139,0127192,01072.4%
2025-09-02134,713600469,88128.7%
2025-08-2996,0970154,98462.0%
2025-08-2864,104427157,84140.6%
2025-08-2771,1320106,01967.1%
2025-08-2668,5260161,22542.5%
2025-08-25108,7770228,04547.7%
2025-08-22130,1430306,02542.5%
2025-08-21294,442197430,01968.5%
2025-08-20123,4560399,02930.9%
2025-08-19154,1980420,30336.7%
2025-08-18188,2580281,40766.9%
2025-08-15120,890500169,13371.5%
2025-08-14223,167250343,55665.0%
2025-08-13429,5006,636623,02468.9%
2025-08-1292,8890187,37349.6%
2025-08-11111,9610435,05325.7%
2025-08-08174,4530295,06259.1%
2025-08-07162,1620434,94437.3%
2025-08-06256,764152527,30048.7%
2025-08-05300,4575,008552,27054.4%
2025-08-0497,018161135,16471.8%
2025-08-01132,8910198,03567.1%
2025-07-31128,2370240,62353.3%
2025-07-30163,1985,000202,60780.5%
2025-07-29230,3770289,25179.6%
2025-07-28304,9630376,50881.0%
2025-07-25539,33098679,52079.4%
2025-07-24190,419102253,75275.0%
2025-07-23203,3370255,55779.6%
2025-07-22111,092171168,25666.0%
2025-07-21147,4950242,90960.7%
2025-07-18218,615432359,52660.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.